MASLD After HCV Cure May Help Sort Residual HCC Risk Into Higher and Lower Tiers
Residual hepatocellular carcinoma risk after HCV eradication remains a stubborn clinical problem. Direct-acting antivirals clear the virus, but they do not erase every pathway that can keep hepatocarcinogenesis alive, especially in patients who carry additional metabolic liver injury after sustained virological response. The Gut study by Chang et al focused on that gap, examining whether metabolic dysfunction-associated steatotic liver disease could help explain why some patients continue to face cancer risk after cure while others do not.
A single virologic endpoint no longer answers the full surveillance question.
The central concern is straightforward: once HCV has been cured, the liver does not always reset to baseline. In some patients, steatosis and broader metabolic dysfunction persist, leaving an inflammatory and fibrotic environment that can continue to support malignant transformation. This is precisely why the study framed MASLD not as a side diagnosis, but as a candidate modifier of post-SVR cancer risk. If metabolic liver disease adds risk on top of prior viral injury, then surveillance strategies that rely only on the fact of HCV cure may miss an important layer of individualization.
Chang and colleagues examined the role of MASLD in shaping HCC risk after cure, with a particular interest in how steatosis severity and metabolic fingerprints may behave in the post-viral setting. The phrase metabolic fingerprints matters here because HCC risk is rarely driven by one isolated variable. In practice, liver cancer emerges from interacting signals: prior fibrosis, persistent steatosis, ongoing metabolic dysfunction, and the residual scar of long-standing chronic hepatitis C. Even after viral clearance, those signals can remain biologically active.
Why Steatosis Still Matters After Sustained Virological Response
Steatosis is not a passive imaging finding. In a liver already injured by HCV, fat accumulation can sustain oxidative stress, promote chronic hepatocyte injury, and amplify fibrogenic pathways. Over time, those processes may preserve the carcinogenic microenvironment even when the original viral trigger has disappeared. For clinicians, this creates a difficult but familiar problem: the treatment has worked virologically, yet the organ system still behaves as though a cancer-promoting substrate is present.
The study’s focus on MASLD reflects a broader shift in hepatology. Post-SVR care can no longer be organized around viral clearance alone, because viral cure and cancer risk are related but not synonymous outcomes. Patients who remain metabolically unhealthy may continue to accumulate risk through steatotic injury, insulin resistance, or other metabolic abnormalities that are captured under the MASLD umbrella. The article makes clear that identifying those patients is crucial to better stratify follow-up and ensure appropriate surveillance intensity.
That distinction reaches beyond epidemiology and into bedside decisions. HCC surveillance is not an abstract exercise; it determines who gets serial imaging, who is seen sooner, and whose small lesion is found early enough to remain within curative options. Early recognition of higher-risk individuals can change the timing of diagnosis and access to treatment. In a disease where stage at detection often determines whether a patient can be treated curatively, surveillance strategy becomes part of cancer therapy.
Individualizing Surveillance After HCV Cure
Current international guidance continues to support ongoing HCC surveillance after SVR in patients with advanced liver disease. The challenge is that advanced fibrosis or cirrhosis does not capture every patient who may still merit close follow-up, while some cured patients without obvious high-risk features may still carry clinically relevant metabolic injury. The study by Chang et al sits squarely in that gray zone, asking whether metabolic phenotyping can sharpen the risk conversation after virologic cure.
This is where the concept of individualised surveillance becomes more than a slogan. A post-SVR patient with persistent steatosis may not resemble a metabolically healthier cured patient, even if both cleared HCV successfully. Their future HCC risk is likely shaped by different combinations of liver injury, and a one-size-fits-all follow-up plan may be too blunt to reflect that difference. Metabolic fingerprints could eventually help separate patients whose risk is driven primarily by fixed structural liver damage from those whose ongoing metabolic disease continues to fuel carcinogenesis.
The biological logic is compelling. Persistent fat in hepatocytes can maintain lipotoxic stress, trigger inflammatory cascades, and perpetuate wound-healing responses that favor fibrosis progression. In a liver that has already endured chronic viral hepatitis, those effects may be additive rather than isolated. The result is a post-cure state in which the virus is gone, but the oncogenic terrain remains partially intact.
What This Means for Hepatology Practice
The practical implication is not that HCV cure has failed. It has succeeded, and decisively. The question is what remains after cure, and which residual abnormalities should be treated as cancer-relevant rather than incidental. MASLD appears to be one of those abnormalities, particularly when steatosis is severe or accompanied by a broader metabolic signature that suggests ongoing disease activity.
For hepatologists, the study reinforces the need to look beyond SVR when deciding who should stay under surveillance. Fibrosis stage remains essential, but it may not be sufficient by itself to capture the full spectrum of post-cure HCC risk. Metabolic assessment, steatosis severity, and the overall burden of metabolic dysfunction deserve attention in the follow-up plan, because they may help explain why some patients remain vulnerable long after viral eradication.
This is also a reminder that surveillance policy and mechanistic understanding have to move together. If metabolic liver disease is contributing to cancer risk after HCV cure, then the liver clinic cannot treat it as a separate, unrelated comorbidity. It becomes part of the cancer risk profile, part of the reason one patient stays on long-term monitoring while another may not need the same intensity of follow-up.
The study does not eliminate uncertainty around exactly how to rank every post-SVR risk factor against every other one. It does, however, place MASLD and steatosis severity firmly inside the conversation about residual HCC risk after HCV cure, where they belong. The remaining challenge is to translate that signal into surveillance rules that are both sensitive enough to catch cancer early and specific enough to avoid unnecessary follow-up in lower-risk patients.